- Multiple Sclerosis patients characteristic, Kingdom of Saudi Arabia.
| Received covid vaccine | ||
| Yes | 685 | (92.8) |
| No | 53 | (7.2) |
| Duration of MS | ||
| < 2 years | 117 | (15.9) |
| 2-5 years | 171 | (23.2) |
| 5-10 years | 199 | (27.0) |
| > 10 years | 251 | (34.0) |
| Medications used | ||
| Gilenya | 120 | (16.3) |
| Betaferon | 113 | (15.3) |
| Others | 107 | (14.5) |
| Ocrevus | 74 | (10.0) |
| Rebif | 63 | (8.5) |
| Tysabri | 58 | (7.9) |
| Aubagio | 58 | (7.9) |
| Tecfidera | 57 | (7.7) |
| Lemtrada | 5 | (.7) |
| Mavenclad | 4 | (.5) |
| Copaxone | 4 | (.5) |
| Mitoxantrone | 4 | (.5) |
| Mayzent | 2 | (.3) |
| None | 91 | (12.3) |
| Dont know | 32 | (4.3) |
| Use vitamin D | ||
| Yes | 558 | (75.6) |
| No | 180 | (24.4) |